Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (FWBI) delivers innovative non-systemic therapies targeting gastrointestinal disorders through advanced recombinant protein research. This page consolidates all official announcements, clinical developments, and strategic updates from the biotechnology innovator.
Investors and researchers will find timely updates on FWBI’s MS1819 recombinant lipase program, financial disclosures, and partnership agreements. Our curated feed ensures access to primary-source materials including trial progress reports, regulatory filings, and executive commentary.
The repository features categorized updates spanning clinical trial milestones, peer-reviewed research publications, and strategic corporate developments. Content is rigorously verified to meet financial reporting standards and therapeutic research accuracy.
Bookmark this page for streamlined tracking of FWBI’s advancements in enzyme deficiency treatments and gastrointestinal health innovation. Regular updates ensure you maintain informed perspectives on this clinical-stage biopharma leader.
On April 25, 2023, First Wave BioPharma announced significant progress in its Phase 2 SPAN clinical trial for adrulipase, a treatment aimed at exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients. The company has surpassed the 50% enrollment target with three U.S. trial sites actively screening patients. The study is a dose-escalation trial involving 12 patients, focusing on safety, tolerability, and efficacy, with topline results expected in July 2023. Adrulipase is a recombinant lipase enzyme designed to aid fat digestion and reduce malabsorption symptoms. Approximately 40,000 U.S. patients suffer from EPI due to cystic fibrosis.
First Wave BioPharma (NASDAQ: FWBI) announced a private placement agreement to issue 1,023,018 shares of common stock at $3.91 each, raising approximately $4.0 million before fees. The agreement includes warrants for an additional 2,046,036 shares at an exercise price of $3.66, valid for five years. The private placement is expected to close around March 15, 2023, subject to customary conditions. Proceeds will be used for working capital. The company plans to file a registration statement for resale of the shares with the SEC shortly. This offering adheres to SEC regulations, limiting sales to registered entities.
